Acaluxen 100 mg (Acalabrutinib) Capsules

Palbo-125 (Palbociclib 125 mg) is a targeted anticancer medicine primarily used in the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. When combined with endocrine therapy, it helps slow the growth and spread of cancer cells by inhibiting key proteins involved in cell division.

Therapeutic Effects:

• Helps delay the progression of advanced breast cancer.
• Reduces the rate of cancer cell multiplication.
• Enhances the effectiveness of hormone therapy.
• Supports long-term disease management in eligible patients.
• May help improve progression-free survival in patients with HR-positive, HER2-negative breast cancer.

Active Ingredient:

• Acalabrutinib INN 100 mg

Composition:
Each hard capsule contains Acalabrutinib INN 100 mg as the active pharmaceutical ingredient. The formulation is designed for oral administration and provides targeted inhibition of Bruton's Tyrosine Kinase (BTK), an important enzyme involved in the growth and survival of malignant B-cells.

Dosage Form:

• Hard Capsule

Route of Administration:

• Oral Use

The dosage should always be determined by an experienced healthcare professional based on the patient's clinical condition, treatment response, and tolerability.

Recommended Adult Dose:

• 100 mg orally twice daily, approximately 12 hours apart.

Administration Instructions:

• Swallow capsules whole with water.
• Do not open, crush, chew, or dissolve the capsule.
• Can be taken with or without food.
• Take doses at the same times each day to maintain consistent drug levels.
• Continue treatment for as long as prescribed by the treating physician.

Missed Dose:

• If a dose is missed by less than 3 hours, take it as soon as remembered.
• If more than 3 hours have passed, skip the missed dose and continue with the next scheduled dose.
• Do not take an extra dose to compensate for a missed dose.

Important Usage Information:

• Regular monitoring may be required during treatment.
• Inform healthcare providers about all medicines and supplements being used.
• Follow all physician recommendations regarding laboratory tests and follow-up assessments.
• Treatment should not be discontinued without medical advice.